Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | FADS1 | O60427 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3079878 | 0.87 | L3MBTL1 (0.59) | L3MBTL1GAANPSR1CA12CA1 | |
| SCHEMBL14254938 | 0.87 | L3MBTL1 (0.59) | L3MBTL1GAANPSR1MAPTHTT | |
| SCHEMBL3786382 | 0.87 | L3MBTL1 (0.59) | L3MBTL1GAANPSR1CA12CA1 | |
| SCHEMBL7074333 | 0.83 | MEN1 (0.43) | L3MBTL1NPSR1CA12CA1CA2 | |
| SCHEMBL14667345 | 0.81 | L3MBTL1 (0.52) | L3MBTL1GAANPSR1CA12CA1 | |
| SCHEMBL3122646 | 0.80 | ALDH1A1 (0.55) | GAANPSR1MAPTHTTALDH1A1 | |
| SCHEMBL31254121 | 0.79 | MAPKAPK2 (0.42) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL6810856 | 0.79 | MAPKAPK2 (0.42) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL8952429 | 0.78 | MEN1 (0.47) | NPSR1MAPTHTTALDH1A1MEN1 | |
| SCHEMBL23441 | 0.77 | L3MBTL1 (0.73) | L3MBTL1GAANPSR1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511059-B2 | Thiazolidinones, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2009-03-31 | — | — | US | disclosed |
| US-7511059-B2 | Thiazolidinones, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2009-03-31 | — | — | US | disclosed |
| US-7511059-B2 | Thiazolidinones, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2009-03-31 | — | — | US | disclosed |
| EP-1844027-A1 | THIAZOLIDINONES FOR USE AS INHIBITORS OF POLO-LIKE KINASE (PLK) | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-10-17 | — | — | EP | disclosed |
| US-20070037862-A1 | inhibitors of polo-like kinases; (4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetonitrile; cancer, auto-immune diseases, cardiovascular diseases | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037862-A1 | inhibitors of polo-like kinases; (4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetonitrile; cancer, auto-immune diseases, cardiovascular diseases | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | US | disclosed |
| CN-1902185-A | Thiazolidinones, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2007-01-24 | — | — | CN | disclosed |
| US-20060223833-A1 | Thiazolidinones, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-10-05 | — | — | US | disclosed |
| WO-2006082107-A1 | THIAZOLIDINONES FOR USE AS INHIBITORS OF POLO-LIKE KINASE (PLK) | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-08-10 | — | — | WO | disclosed |
| EP-1678153-A1 | THIOZOLIDINONES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | Schering Aktiengesellschaft (DE) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042505-A1 | THIOZOLIDINONES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037862-A1 | inhibitors of polo-like kinases; (4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetonitrile; cancer, auto-immune diseases, cardiovascular diseases | PLK2, PLK4, PDXK | L3MBTL1 689/4885GAA 1502/4885NPSR1 4634/4885 |
| US-20060223833-A1 | Thiazolidinones, their production and use as pharmaceutical agents | PLK2, PLK4, PLK3 | L3MBTL1 4002/4885GAA 366/4885NPSR1 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.